CompoAtlas

AMP Women's Ripped Vitapak

Originaltext auf Französisch.

AMP Women's Ripped Vitapak, NPN 80082614: in Kanada zugelassenes Naturgesundheitsprodukt. Medizinische Inhaltsstoffe: Folate, Vitamine B12, Panax ginseng, Magnésium.

Falls dieses Produkt in Frankreich verkauft würde

Eine Tagesmenge wird nur bei ausdrücklicher oraler Dosierung für Erwachsene berechnet, die pro Tag und in einer zur Produktform passenden festen Einheit angegeben ist. Mehrdeutige Einheiten, Flüssigkeiten, Pulver und pädiatrische Dosen werden nicht hochgerechnet. Eine nicht berechnete Menge wird nicht mit Dosisgrenzwerten verglichen. Diese Analyse stellt weder eine Verkaufszulassung in Frankreich noch eine Sicherheits- oder Wirksamkeitsbewertung dar.

Zusammensetzung

Arzneilicher Inhaltsstoff und QuelleJe Dosiseinheit laut QuelleTäglich höchstens, Erwachsene
Folate

Quelle : Folate

200 mcgNicht berechnet
Vitamine B12

Quelle : Cyanocobalamine

500 mcgNicht berechnet
Panax ginseng

Quelle : Racine

Extraktionsverhältnis : 5:1

Trockenpflanzenäquivalent : 112,5 mg

22,5 mgNicht berechnet
Magnésium

Quelle : Citrate de magnésium

50 mgNicht berechnet
Manganèse

Quelle : Citrate de manganèse (II)

1 mgNicht berechnet
Vitamine B6

Quelle : Chlorhydrate de pyridoxine

50 mgNicht berechnet
Vitamine A

Quelle : Acetate

Stärke : 1.250 UI

375 mcg EARNicht berechnet
Arctostaphylos uva-ursi

Quelle : Arctostaphylos uva-ursi - feuille

Extraktionsverhältnis : 3:1

Trockenpflanzenäquivalent : 30 mg

10 mgNicht berechnet
Biotine

Quelle : Biotine

2.500 mcgNicht berechnet
Piperine

Quelle : Piper nigrum - fruit

5 mgNicht berechnet
(3R,3'S)-beta, beta-Carotene-3,3'-diol

Quelle : L'oléorésine de Tagetes erecta

95 mcgNicht berechnet
(3R,3'R,6'R)-beta,epsilon-Carotene-3,3'-diol

Quelle : L'oléorésine de Tagetes erecta

475 mcgNicht berechnet
Lycopène tout trans475 mcgNicht berechnet
2-hydroxy-N,N,N-triméthyléthanaminium

Quelle : Bitartrate de choline

5 mgNicht berechnet
1,2,3,5/4,6- hexahydroxycyclohexane

Quelle : Inositol

5 mgNicht berechnet
2,5-Cyclohexadiène-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-décaméthyl-2,6,10,14,18,22,26,30,34,38-tétracontadécaényl]-5,6-diméthoxy-3-méthyl

Quelle : Coenzyme Q10

40 mgNicht berechnet
3,3'-dihydroxy-4,4'-diketo-bêta-carotène

Quelle : Astaxanthin

25 mcgNicht berechnet
3-Pyridinecarboxamide

Quelle : Nicotinamide

15 mgNicht berechnet
Biotine

Quelle : Biotine

150 mcgNicht berechnet
Boron

Quelle : Citrate de bore

350 mcgNicht berechnet
Calcium

Quelle : Carbonate de calcium

250 mgNicht berechnet
Chrome

Quelle : Citrate de chrome(III)

60 mcgNicht berechnet
Cuivre

Quelle : Citrate cuivrique

1 mgNicht berechnet
Acide d-pantothénique

Quelle : D-Pantothénate de calcium

25 mgNicht berechnet
Acide DL-alpha lipoÏque

Quelle : Acide DL-alpha-lipoÏque

12,5 mgNicht berechnet
Iode

Quelle : Iodure de potassium

75 mcgNicht berechnet
Molybdène

Quelle : Citrate de molybdène

37,5 mcgNicht berechnet
Niacine

Quelle : Niacine

10 mgNicht berechnet
Juniperus communis

Quelle : Juniperus communis - Fruit

Extraktionsverhältnis : 2:1

Trockenpflanzenäquivalent : 600 mg

300 mgNicht berechnet
Magnésium

Quelle : Oxide

20 mgNicht berechnet
Vanadium

Quelle : Citrate de vanadium

5 mcgNicht berechnet
bêta-carotène

Quelle : bêta-carotène

Stärke : 3.750 UI

2.250 mcgNicht berechnet
Niacine

Quelle : Niacine

20 mgNicht berechnet
Acide linoléique conjugué

Quelle : Free fatty acid form derived from processed safflower oil

1.000 mgNicht berechnet
Allium sativum

Quelle : Allium sativum - Bulbe

10 mgNicht berechnet
Vitamine B6

Quelle : Chlorhydrate de pyridoxine

25 mgNicht berechnet
Riboflavine

Quelle : Riboflavine

25 mgNicht berechnet
Sélénium

Quelle : Produit de chélation de sélénium et de protéine végétale hydrolysée (PVH)

75 mcgNicht berechnet
Silicium

Quelle : Dioxyde de silicium

2 mgNicht berechnet
Thiamine

Quelle : Chlorhydrate de thiamine

25 mgNicht berechnet
Vitamine C

Quelle : Vitamine C

150 mgNicht berechnet
Vitamine D

Quelle : Cholécalciférol

Stärke : 500 UI

12,5 mcgNicht berechnet
Vitamine E

Quelle : Succinate d'acide de d-alpha tocophéryle

Stärke : 15 UI

10,05 mg ATNicht berechnet
Vitamin K2

Quelle : Ménatétrénone

40 mcgNicht berechnet
Zinc

Quelle : Citrate de zinc

7,5 mgNicht berechnet
Sambucus nigra

Quelle : Sambucus nigra - fruit

30 mgNicht berechnet
Potassium

Quelle : Chloride

20 mgNicht berechnet
Capsicum annuum

Quelle : Fruit

Extraktionsverhältnis : 8:1

Trockenpflanzenäquivalent : 266,72 mg

33,34 mgNicht berechnet
Caféine200 mgNicht berechnet

Nicht arzneiliche Inhaltsstoffe

Hydroxypropylméthylcellulose, Cellulose microcristalline, Gélatine, Poly(alcool vinylique), Stéarate de magnésium, Talc, cellulose, Hydroxypropylcellulose, FD&C Blue #1, Glycérine, Alcool isopropylique, Jaune FD&C n° 6, FD & C Jaune no. 6, Dioxyde de titane, Dicalcium phosphate, Dioxyde de silicium, Laque d'aluminium jaune D&C n° 10, Rouge FD & C #3, Calcium silicate, Macrogol 400, Carbonate de calcium

In Kanada empfohlene Dosen

BevölkerungsgruppeAlterMenge pro EinnahmeHäufigkeit
Adultes de sexe fémininNon précisée1 Vitapak1 Tous les jours

In Kanada zugelassene Verwendungen

GNC Women's Ultra Mega Energy Calcium intake, when combined with sufficient vitamin D, a healthy diet, and regular exercise, may reduce the risk of developing osteoporosis. Helps in the maintenance of bones. Helps the body to metabolize carbohydrates, fats and proteins. Helps normal growth. Helps in tissue formation. Helps normal growth and development. Helps the body to metabolize proteins. Helps to form red blood cells. Helps to maintain proper muscle function. Helps in the function of the thyroid gland. Helps to maintain healthy skin. Helps to maintain immune function. Helps to produce and repair connective tissue. Helps in the development and maintenance of bones. Provides support for healthy glucose metabolism. Helps the body to metabolize carbohydrates and fats. Helps to maintain and/or support cardiovascular health. Plays a vital role in energy production. Supports energy production. Facilitates energy production at cellular level. Provides antioxidants for the maintenance of good health. Antioxidant for the maintenance of good health.

Originaltext auf Englisch.

GNC Women's Ultra Mega Energy Vitamin supplement, mineral supplement, vitamin/mineral supplement, multi-vitamin, multi-mineral or multi-vitamin/mineral. A factor in the maintenance of good health (for active women). Helps to maintain eyesight, healthy skin, membranes and immune function. Helps in the development and maintenance of night vision. Helps in the development and maintenance of bones and teeth. Source of vitamin A for the maintenance of good health. Provitamin A for the maintenance of good health. Source of vitamin A to help maintain eyesight, skin, membranes and immune function. Provitamin A to help maintain eyesight, skin, membranes and immune function. Source of vitamin A to help in the development and maintenance of night vision. Provitamin A to help in the development and maintenance of night vision. Source of vitamin A to help in the development and maintenance of bones and teeth. Provitamin A to help in the development and maintenance of bones and teeth. Helps the body to metabolize fats and proteins. Helps in the development and maintenance of bones, cartilage, teeth and gums. Helps in connective tissue formation. Helps in wound healing. An antioxidant for the maintenance of good health. Helps in the absorption and use of calcium and phosphorus.

Originaltext auf Englisch.

WATEREX Juniper is traditionally used in Herbal Medicine as a diuretic. CLA May help to support a modest improvement to body composition when used with a program of reduced intake of dietary calories and increased physical activity. May help to support a modest reduction in fat mass when used with a program of reduced intake of dietary calories and increased physical activity. BIOTIN 2500 N/A X12 Cayenne is traditionally used in Herbal Medicine to aid digestion; to help support peripheral circulation. Helps (temporarily) to promote alertness and wakefulness, and to enhance cognitive performance. Helps (temporarily) to relieve fatigue, to promote endurance, and to enhance motor performance. Used (temporarily) as a mild diuretic. VITAMIN B6 Helps to prevent vitamin B6 deficiency

Originaltext auf Englisch.

Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.

Warnhinweise in Kanada

Contra-Indications : Do not use if you are allergic to plants of the Asteraceae/Compositae/Daisy family. Do not use if you are pregnant or breastfeeding. Do not use if you have kidney disorder. If you have heart disease, high or low blood pressure, kidney or liver disorder, diabetes or edema (swelling of hands, face and feet), or are taking products containing diuretics, do not use. Do not use if you have CVD, diabetes, metabolic syndrome or insulin resistance. Do not take with highly acidic foods or medications which may acidify urine.

Originaltext auf Englisch.

Cautions and Warnings : Consult a health care practitioner prior to use if you are taking protease inhibitors or blood thinners. Consult a health care practitioner prior to use if you are taking blood pressure medication. Consult a health care practitioner prior to use if you have diabetes. Consult a health care practitioner prior to use if you have heart disease. Consult a health care practitioner prior to use if you are taking medication or other dietary supplements. If you have stomach ulcers or inflammation, consult a health care practitioner prior to use. Keep out of reach of children. If overdose or accidental ingestion occurs, call a Poison Control Center immediately. Consult a health care practitioner prior to use if you are taking lithium. Consult a health care practitioner prior to use if have high blood pressure, glaucoma, and/or detrusor instability (overactive bladder syndrome). Consumption with natural health products (e.g. bitter orange extract, synephrine, octopamine, ephedra) or other drug (e.g. ephedrine) which increase blood pressure is not recommended. Consumption with other caffeine-containing products (e.g. medications, coffee, tea, colas, cocoa, guarana, mate) is not recommended. This product is not intended as a substitute for sleep. Consult a health care practitioner prior to use if you are obese or if you have cardiovascular disease (CDV) risk factors (e.g. high blood pressure, high cholesterol and/or triglycerides). Consult a health care practitioner prior to use if your goal is to achieve weight loss. Consult a health care practitioner if symptoms persist or worsen. Some people may experience gastrointestinal upset. If you are taking any other medications or natural health products, consult a health care practitioner prior to use, as black pepper/piperine may alter their effectiveness. Stop use and seek medical attention immediately if you experience dizziness, confusion, muscle weakness or pain, abnormal heart beat and/or difficulty breathing.

Originaltext auf Englisch.

Known Adverse Reactions : People sensitive to nicotinic acid may experience flushing of the skin that is generally mild and transient. Hypersensitivity/allergy, is known to occur, in which case, discontinue use. Stomach/abdominal pain has been known to occur, in which case, discontinue use.

Originaltext auf Englisch.

Produktdaten

Inhaber
GNC Canada Holdings ULC
NPN oder DIN-HM
80082614
Status
Lizenz nicht aktiv
Lizenzdatum
24. Januar 2018
Überarbeitungsdatum
27. Februar 2018
Form
Kit
Verabreichungsweg
Orale
Art des Antrags
Non traditionnelle

Quelle

Amtlicher Health-Canada-Eintrag, Zulassung 80082614

Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Originaltext auf Englisch.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Originaltext auf Französisch.

Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.

Offizielle Warnhinweise (Health Canada)

Health Canada veröffentlicht Warnhinweise zu diesen Zutaten:

  • Panax ginseng
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    PANAX GINSENG

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Vuksan et al. 2008; Seely et al. 2008; Sievenpiper et al. 2006; ESCOP 2003; Tetsutani et al. 2000; Sotaniemi et al. 1995; Chin 1991).

    Von Health Canada zitierte Quellen (8)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Chin RKH. Ginseng and common pregnancy disorders. Asia-Oceania Journal of Obstetrics and Gynaecology 1991;17(4):379-380. PubMed
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Seely D, Dugoua JJ, Perri D, Mills E, Koren G. Safety and efficacy of Panax ginseng during pregnancy and lactation. The Canadian Journal of Clinical Pharmacology 2008;15(1):e87-e94.
    • Sievenpiper JL, Sung MK, Buono MD, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006;25(2):100-107. PubMed Randomisierte Studie
    • Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care 1995;18(10):1373-1375. PubMed Klinische Studie
    • Tetsutani T, Yamamura M, Yamaguchi T, Onoyama O, Kono M. Can red ginseng control blood glucose in diabetic patients. The Ginseng Review 2000;28:44-47.
    • Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Buono MD, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism & Cardiovascular Diseases 2008;18(1):46-56. PubMed Randomisierte Studie

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking antidepressant medication, blood thinners or digoxin (Brinker 2010; Lee et al. 2008a; Dasgupta and Reyes 2005; Janetzki and Morreale 1997; Gonzalez-Seijo et al. 1995; Shader and Greenblatt 1988; Jones and Runikis 1987; Shader and Greenblatt 1985).

    Von Health Canada zitierte Quellen (8)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Dasgupta A, Reyes MA. Effect of Brazillian, Indian, Siberian, Asian, and North American ginseng on serum digoxin measurement by immunoassays and binding of digoxin-like immunoreactive components of ginseng with Fab Fragment of antidigoxin antibody (Digiband). American Journal of Clinical Pathology 2005;124(2):229-236. PubMed
    • Gonzalez-Seijo JC, Ramos YM, Lastra I. Manic episode and ginseng: report of a possible case. Journal of Clinical Psychopharmacology 1995;15(6):447-448. PubMed Fallbericht
    • Janetzki K, Morreale AP. Probable interaction between warfarin and ginseng. American Journal of Health-System Pharmacy 1997;54(6):692-693.
    • Jones BD, Runikis AM. Interaction of ginseng with phenelzine. Journal of Clinical Pharmacology 1987;7(3):201-202. PubMed Fallbericht
    • Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin and Panax ginseng in ischemic stroke patients. The Journal of Alternative and Complementary Medicine 2008a;14(6):715-721. PubMed Randomisierte Studie
    • Shader RI, Greenblatt DJ. Bees, ginseng and MAOIs revisited. Journal of Clinical Psychopharmacology 1988;8(4):235. PubMed Fallbericht
    • Shader RI, Greenblatt DJ. Phenelzine and the dream machine – ramblings and reflections. Journal of Clinical Psychopharmacology 1985;5(2):65. PubMed Fallbericht

    Gegenanzeigen

    Anwendungsbedingung: Traditional Chinese Medicine.

    Do not use in cases of yin deficiency with heat signs, heat excess, or in the absence of significant qi deficiency (Bensky et al. 2004).

    Von Health Canada zitierte Quellen (1)
    • Bensky D, Clavey, Stöger E, Gamble A. Chinese Herbal Medicine: Materia Medica. 3rd edition. Seattle (WA): Eastland Press, Incorporated; 2004.

    Bekannte Nebenwirkungen

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience insomnia, anxiety or headaches (Lee et al. 2008b; Vuksan et al 2008; de Andrade et al.2007; Sievenpiper et al. 2006; Coon and Ernst 2002; Ellis and Reddy 2002; Scaglione et al. 2001; Siegel 1979).

    Von Health Canada zitierte Quellen (8)
    • Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Safety 2002;25(5):323-344. PubMed Systematische Übersicht
    • de Andrade E, de Masquita AA, de Almeida Claro J, de Andrade PM, Ortiz V, Paranhos M, Srougi M. Study of the efficacy of Korean Red Ginseng in the treatment of erectile dysfunction. Asian Journal of Andrology 2007;9(2):241-244.
    • Ellis JM, Reddy P. Effects of Panax ginseng on quality of life. The Annals of Pharmacotherapy 2002;36(3):375-379. PubMed Randomisierte Studie
    • Lee ST, Chu K, Sim JY, Heo JH, Kim M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Disease and Associated Disorders 2008b;22(3):222-226. PubMed Randomisierte Studie
    • Scaglione F, Weiser K, Alessandria M. Effects of the standardised ginseng extract G115 in patients with chronic bronchitis. Clinical Drug Investigation 2001;21(1):41-45.
    • Siegel RK. Ginseng abuse syndrome. Problems with the panacea. The Journal of the American Medical Association 1979;241(15):1614-1615. PubMed
    • Sievenpiper JL, Sung MK, Buono MD, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006;25(2):100-107. PubMed Randomisierte Studie
    • Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Buono MD, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism & Cardiovascular Diseases 2008;18(1):46-56. PubMed Randomisierte Studie

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    Monografie von Health Canada vom 27. Juni 2025

  • Arctostaphylos uva-ursi
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    Bearberry - Arctostaphylos Uva-Ursi

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Gilt für Produkte: providing 60 milligrams or more of dried leaves and/or products providing 20 milligrams or more of Arbutin, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder, fever, painful urination (dysuria), spasms, or blood in urine (EMA 2018; Duke 2002; Newall 1996).

    Von Health Canada zitierte Quellen (2)
    • EMA 2018: EMA/HMPC/750269/2016. European Union herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium. London (GB): European Medicines Agency: Committee on Herbal Medicinal Products (HMPC); 2018 January 30. [Accessed 2024 June 11]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-arctostaphylos-uva-ursi-l-spreng-folium-revision-2_en.pdf
    • Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A guide for health-care professionals. London (GB): The Pharmaceutical Press; 1996.

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    Gegenanzeigen

    Do not use if you are pregnant or breastfeeding (EMA 2018; Brinker 2010; ESCOP 2003; WHO 2002; Blumenthal 2000; Mills and Bone 2000; Bradley 1992).

    Von Health Canada zitierte Quellen (8)
    • Blumenthal M, Goldberg A, Brinckmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
    • Bradley PR, editor. British Herbal Compendium Volume 1: A Handbook of Scientific Information on Widely Used Plant Drugs - Companion Volume 1 of the British Herbal Pharmacopoeia. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2018: EMA/HMPC/750269/2016. European Union herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium. London (GB): European Medicines Agency: Committee on Herbal Medicinal Products (HMPC); 2018 January 30. [Accessed 2024 June 11]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-arctostaphylos-uva-ursi-l-spreng-folium-revision-2_en.pdf
    • ESCOP 2003: European Scientific Cooperative of Phytotherapy. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition completely revised and expanded. Exeter (GB): European Scientific Cooperative on Phytotheraphy; 2003.
    • Mills S, Bone K. Principles and Practice of Phytotherapy, Modern Herbal Medicine. Edinburg (GB): Churchill LYes Soivingston; 2000.
    • WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 3. Geneva (CH): World Health Organization; 2002.
    • OMS 2002: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 3. Genève (CH): Organisation mondiale de la santé; 2002.

    Monografie von Health Canada vom 30. Januar 2026

  • Piperine
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    BLACK/WHITE PEPPER - PIPER NIGRUM

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications or any other health products, as black/white pepper/piperine may alter their effectiveness (Han 2011; Srinivasan 2007; Khajuria et al. 2002; Bano et al. 1991).1

    Von Health Canada zitierte Quellen (4)
    • Bano G, Raina RK, Zutshi U, Bedi KL, Johri RK, Sharma SC. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. European Journal of Pharmacology 1991;41(6):615-7. PubMed
    • Han HK. The effects of black pepper on the intestinal absorption and hepatic metabolism of drugs. Expert Opinion on Drug Metabolism & Toxicology 2011;7(6):721-729. PubMed Übersichtsartikel
    • Khajuria A, Thusu N, Zutshi U. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. Phytomedicine 2002;9(3):224-31. PubMed
    • Srinivasan K. Black Pepper and its pungent principle-piperine: a review of diverse physiological effects. Critical Reviews in Food Science and Nutrition 2007;47(8):735-748. PubMed Übersichtsartikel

    1Note: At subtherapeutic quantities, the risk statement regarding the alteration of effectiveness is not required for products providing 25 mg or less Piper nigrum fruit per day for Class II and III applications.

    Anwendungsbedingung: Improve digestion.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Anwendungsbedingung: Vermifuge/anthelmintic.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or persist for more than 2 weeks.

    Monografie von Health Canada vom 19. Dezember 2025

  • Juniperus communis
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    Juniper - Juniperus Communis

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Mills et al. 2006).

    Von Health Canada zitierte Quellen (1)
    • Mills E, Dugoua J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation: An Evidence-Based Approach. London (UK): Taylor and Francis Medical; 2006.

    Gegenanzeigen

    Do not use if you are pregnant (Brinker 2010; Bradley 2006; ESCOP 2003; Hoffmann 2003).

    Von Health Canada zitierte Quellen (4)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (UK): British Herbal Medicine Association; 2006.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.

    Do not use if you have a kidney disorder (Brinker 2010; Bradley 2006; ESCOP 2003; Hoffmann 2003).

    Von Health Canada zitierte Quellen (4)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (UK): British Herbal Medicine Association; 2006.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.

    Monografie von Health Canada vom 31. Januar 2025

  • Acide linoléique conjugué
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    CONJUGATED LINOLEIC ACID

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are obese or have cardiovascular disease (CVD) risk factors (Tholstrup et al. 2008; Gaullier et al. 2007; Steck et al. 2007; Larsen et al. 2006; Taylor et al. 2006; Gaullier et al. 2005; Smedman et al. 2005; Gaullier et al. 2004; Basu et al. 2000a,b).

    Von Health Canada zitierte Quellen (9)
    • Basu S, Risérus U, Turpeinen A, Vessby B. 2000a. Conjugated linoleic acid induces lipid peroxidation in men with abdominal obesity. Clinical Science 99(6):511-516.
    • Gaullier JM, Halse J, Høivik HO, Høye K, Syvertsen C, Nurminiemi M, Hassfeld C, Einerhand A, O'Shea M, Gudmundsen O. 2007. Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese. British Journal of Nutrition 97(3):550-560.
    • Gaullier JM, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O. 2004. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. The American Journal of Clinical Nutrition 79:1118-1125.
    • Gaullier JM, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O. 2005. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. The Journal of Nutrition 135(4):778-784.
    • Larsen TM, Toubro S, Gundmensen O, Astrup A. 2006. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat gain. The American Journal of Clinical Nutrition 83(3):606-612.
    • Smedman A, Basu S, Jovinge S, Fredrikson GN, Vessby B. 2005. Conjugated linoleic acid increased C-reactive protein in human subjects. British Journal of Nutrition 94(5):791-795.
    • Steck SE, Chalecki AM, Miller P, Conway J, Austin GL, Hardin JW, Albright CD, Thuillier P. 2007. Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans. The Journal of Nutrition 137(5):1188-1193.
    • Taylor JS, Williams SR, Rhys R, James P, Frenneaux MP. 2006. Conjugated linoleic acid impairs endothelial function. Arteriosclerosis, Thrombosis, and Vascular Biology 26(2):307-312.
    • Tholstrup T, Raff M, Straarup EM, Lund P, Basu S, Bruun JM. 2008. An oil mixture with trans-10, cis-12 conjugated linoleic acid increases markers of inflammation and in vivo lipid peroxidation compared with cis-9, trans-11 conjugated linoleic acid in postmenopausal women. The Journal of Nutrition 138(8):1445-1451.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if your goal is to achieve weight loss.

    Gegenanzeigen

    Do not use if you are pregnant (HC 2010).

    Von Health Canada zitierte Quellen (2)
    • HC 2010: Health Canada: Prenatal Nutrition Guidelines for health Professionals: Gestational weight gain [Accessed 2024 April 7]. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-eng.pdf
    • SC 2010 : Santé Canada : Lignes directrices sur la nutrition pendant la grossesse à l'intention des professionnels de la santé : Gain de poids pendant la grossesse. [Consulté le 7 avril 2024]. Disponible à : https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-fra.pdf

    Do not use if you have cardiovascular disease (CVD), diabetes, metabolic syndrome or insulin resistance (Tholstrup et al. 2008; Gaullier et al. 2007; Steck et al. 2007; Larsen et al. 2006; Taylor et al. 2006; Gaullier et al. 2005; Smedman et al. 2005; Gaullier et al. 2004; Moloney et al. 2004; Basu et al. 2000a,b).

    Von Health Canada zitierte Quellen (10)
    • Basu S, Risérus U, Turpeinen A, Vessby B. 2000a. Conjugated linoleic acid induces lipid peroxidation in men with abdominal obesity. Clinical Science 99(6):511-516.
    • Gaullier JM, Halse J, Høivik HO, Høye K, Syvertsen C, Nurminiemi M, Hassfeld C, Einerhand A, O'Shea M, Gudmundsen O. 2007. Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese. British Journal of Nutrition 97(3):550-560.
    • Gaullier JM, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O. 2004. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. The American Journal of Clinical Nutrition 79:1118-1125.
    • Gaullier JM, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O. 2005. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. The Journal of Nutrition 135(4):778-784.
    • Larsen TM, Toubro S, Gundmensen O, Astrup A. 2006. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat gain. The American Journal of Clinical Nutrition 83(3):606-612.
    • Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM. 2004. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. The American Journal of Clinical Nutrition 80(4):887-895.
    • Smedman A, Basu S, Jovinge S, Fredrikson GN, Vessby B. 2005. Conjugated linoleic acid increased C-reactive protein in human subjects. British Journal of Nutrition 94(5):791-795.
    • Steck SE, Chalecki AM, Miller P, Conway J, Austin GL, Hardin JW, Albright CD, Thuillier P. 2007. Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans. The Journal of Nutrition 137(5):1188-1193.
    • Taylor JS, Williams SR, Rhys R, James P, Frenneaux MP. 2006. Conjugated linoleic acid impairs endothelial function. Arteriosclerosis, Thrombosis, and Vascular Biology 26(2):307-312.
    • Tholstrup T, Raff M, Straarup EM, Lund P, Basu S, Bruun JM. 2008. An oil mixture with trans-10, cis-12 conjugated linoleic acid increases markers of inflammation and in vivo lipid peroxidation compared with cis-9, trans-11 conjugated linoleic acid in postmenopausal women. The Journal of Nutrition 138(8):1445-1451.

    Bekannte Nebenwirkungen

    When using this product you may experience gastrointestinal discomfort/disturbances (Gaullier et al. 2007; Pinkoski et al. 2006; Berven et al. 2000; Blankson et al. 2000).

    Von Health Canada zitierte Quellen (4)
    • Berven G, Bye A, Hals O, Blankson H, Fagertun H, Thom E, Wadstein J, Gudmundsen O. 2000. Safety of conjugated linoleic acid (CLA) in overweight and obese human volunteers. European Journal of Lipid Science and Technology 102(7):455-462.
    • Blankson H, Stakkestad JA, Fagertun H, Thom E, Wadstein J, Gudmundsen O. 2000. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. The Journal of Nutrition 130(12):2943-2948.
    • Gaullier JM, Halse J, Høivik HO, Høye K, Syvertsen C, Nurminiemi M, Hassfeld C, Einerhand A, O'Shea M, Gudmundsen O. 2007. Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese. British Journal of Nutrition 97(3):550-560.
    • Pinkoski C, Chilibeck PD, Candow DG, Esliger D, Ewaschuk JB, Facci M, Farthing JP, Zello GA. 2006. The effects of conjugated linoleic acid supplementation during resistance training. Medicine and Science in Sports and Exercise 38(2):339-348.

    Monografie von Health Canada vom 10. Januar 2025

  • Allium sativum
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    Garlic - Allium sativum

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: Relief of upper respiratory tract infections and catarrhal (nasal congestion) conditions.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Anwendungsbedingung: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or protease inhibitors (Brinker 2010; Mills and Bone 2005).

    Von Health Canada zitierte Quellen (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills and Bone 2005).

    Von Health Canada zitierte Quellen (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).

    Von Health Canada zitierte Quellen (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Bekannte Nebenwirkungen

    Stop use if hypersensitivity/allergy occurs (Brinker 2010; Mills and Bone 2005).

    Von Health Canada zitierte Quellen (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Monografie von Health Canada vom 30. Januar 2026

  • Vitamine D
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    VITAMIN D (>1,000 - 2,500 IU)

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products except products containing zinc sourced from picolinate requiring a contraindication.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney disorders (NIH 2024; BfR 2020).

    Von Health Canada zitierte Quellen (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other supplements or products containing vitamin D or vitamin D analogues.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any medications including antacids, anticonvulsants, digoxin, cholestyramine, colestipol, mineral oil, steroids, statins or thiazide diuretics (NNHPD 2021; BfR 2020).

    Von Health Canada zitierte Quellen (3)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NNHPD 2021. Natural and Non-Prescription Health Products Directorate. Internal evidence and HC's product monographs.
    • DPSNSO 2021. Direction des produits de santé naturels et sans ordonnance. Preuves internes et monographies de produits internes de SC.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to determine if you would benefit from additional vitamin D as 15-20 mcg (600-800 IU) of vitamin D per day is an adequate quantity for most individuals.

    Gilt für Produkte: containing vitamin K2.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (NNHPD 2026).

    Von Health Canada zitierte Quellen (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Gilt für Produkte: providing 25-34 mg of zinc per day for adults 18 years or 31-50 mg of zinc per day for adults 19 years and older.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are unsure whether you are taking enough copper as zinc supplementation can cause a copper deficiency (NNHPD 2026).

    Von Health Canada zitierte Quellen (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Gegenanzeigen

    Anwendungsbedingung: All products.

    Do not use if you have hypercalcemia and/or hypercalciuria (NIH 2024; BfR 2020).

    Von Health Canada zitierte Quellen (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Gilt für Produkte: containing zinc sourced from picolinate.

    Do not use if you are pregnant or breastfeeding (NNHPD 2026).

    Von Health Canada zitierte Quellen (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Bekannte Nebenwirkungen

    Anwendungsbedingung: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if the following early symptoms of hypercalcemia occur: weakness, fatigue, drowsiness, headache, lack of appetite, dry mouth, metallic taste, nausea, vomiting, vertigo, ringing in the ears, lack of coordination and muscle weakness or if you develop any other symptom (NIH 2024; BfR 2020).

    Von Health Canada zitierte Quellen (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Gilt für Produkte: providing more than 350 mg of magnesium per day.

    When using this product you may experience diarrhea (NNHPD 2026).

    Von Health Canada zitierte Quellen (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Monografie von Health Canada vom 26. Juni 2026

  • Sambucus nigra
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    ELDER – SAMBUCUS

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Anwendungsbedingung: Diaphoretic; Symptoms of colds, flus; Sinusitis, hay-fever; Joint pain.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Bekannte Nebenwirkungen

    Anwendungsbedingung: All products.

    Stop use if hypersensitivity/allergy occur (Forster-Waldl et al. 2003).

    Von Health Canada zitierte Quellen (1)
    • Förster-Waldl E, Marchetii M, Schöll I, Focke M, Radauer C, Kinaciyan T, Nentwich I, Jäger S, Schmid ER, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Type I allergy to elderberry (Sambucus nigra) is elicited by a 33.2 kDa allergen with significant homology to ribosomal inactivating proteins. Clinical and Experimental Allergy 2003;33(2):1703-1710. PubMed

    Anwendungsbedingung: All products except those making a diuretic claim.

    When using this product diuretic effect may occur (Bradley 1992; Winston and Kuhn 2008; Barnes et al. 2007; Hoffman 2003).

    Von Health Canada zitierte Quellen (2)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines. 3rd edition. London (GB): The Pharmaceutical Press; 2007.
    • Winston D and Kuhn MA. Herbal Therapy & Supplements A Scientific and Traditional Approach. Philadelphia (PA): Lippincott Williams & Wilkins; 2008.

    2 im Text zitierte Studien haben keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    Monografie von Health Canada vom 19. Dezember 2025

  • Capsicum annuum
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    CAYENNE - CAPSICUM ANNUUM Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).

    Von Health Canada zitierte Quellen (1)
    • CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).

    Von Health Canada zitierte Quellen (2)
    • Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).

    Von Health Canada zitierte Quellen (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Anwendungsbedingung: Digestion; Peripheral circulation.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografie von Health Canada vom 27. März 2026

    CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    For external use only (US FDA 2023).

    Von Health Canada zitierte Quellen (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).

    Von Health Canada zitierte Quellen (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).

    Von Health Canada zitierte Quellen (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).

    Von Health Canada zitierte Quellen (1)
    • CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Bekannte Nebenwirkungen

    Anwendungsbedingung: All products.

    Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).

    Von Health Canada zitierte Quellen (5)
    • APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
    • Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
    • McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Randomisierte Studie
    • Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Systematische Übersicht

    Monografie von Health Canada vom 27. März 2026

  • Caféine
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    CAFFEINE

    Art der Anwendung: Oral (Higdon and Frei 2006)

    Vorsichtsmaßnahmen und Warnhinweise

    Gilt für Produkte: providing 100 mg to 400 mg caffeine, per day1.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

    Von Health Canada zitierte Quellen (7)
    • Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
    • Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Randomisierte Studie
    • Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
    • Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Übersichtsartikel
    • Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Klinische Studie
    • Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Metaanalyse
    • Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Metaanalyse

    1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

    Gilt für Produkte: providing more than 300 mg caffeine, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant, breastfeeding, or attempting to conceive (Nawrot et al. 2003).

    Von Health Canada zitierte Quellen (1)
    • Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Additives and Contaminants 2003;20(1):1-30. PubMed Übersichtsartikel

    Gilt für Produkte: providing 400 mg or more caffeine, per day.

    When using this product avoid taking other health products, foods or beverages that contain caffeine and/or increase blood pressure (FDA 2023; Bui et al. 2006; Bouchard et al. 2005; Haller et al. 2005; NIH 2004; Berardi et al. 2002; Vahedi et al. 2000; Zimmerman 1992).

    Von Health Canada zitierte Quellen (8)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • Bouchard NC, Howland MA, Greller HA, Hoffman RS, Nelson LS. Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clinic Proceeding 2005;80(4):541-545. PubMed Fallbericht
    • Bui LT, Nguyen DT, Ambrose PJ. Blood pressure and heart rate effects following a single dose of bitter orange. The Annals of Pharmacotherapy 2006;40(1):53-57. PubMed Randomisierte Studie
    • FDA 2023: Food and Drug Administration. Title 21 Chapter 1 Part 340. Stimulant drug products for over-the-counter human use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services; 2023. [Accessed 2023 Aug 28]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=340&showFR=1
    • Haller CA, Benowitz NL, Jacob P. Hemodynamic effects of ephedra-free weight-loss supplements in humans. The American Journal of Medicine 2005;118(9):998-1003. PubMed Randomisierte Studie
    • NIH 2004: National Institutes of Health. Office of Dietary Supplements. Fact sheets. Ephedra and ephedrine alkaloids for weight loss and athletic performance; 2004. [Accessed 2023 August 28]. Available from: https://ods.od.nih.gov/factsheets/ephedraandephedrine-HealthProfessional/.
    • Vahedi K, Domingo V, Amarenco P, Bousser MG. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. Journal of Neurology, Neurosurgery and Psychiatry 2000;68(1):112-113. PubMed Fallbericht
    • Zimmerman DR. Zimmerman's Complete Guide to Nonprescription Drugs, 2nd edition. Detroit (MI): Gale Research Inc.; 1992.

    Gegenanzeigen

    Gilt für Produkte: providing more than 400 mg caffeine per day.

    Do not use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

    Von Health Canada zitierte Quellen (7)
    • Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
    • Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Randomisierte Studie
    • Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
    • Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Übersichtsartikel
    • Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Klinische Studie
    • Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Metaanalyse
    • Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Metaanalyse

    Bekannte Nebenwirkungen

    Anwendungsbedingung: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if hypersensitivity/allergy occurs (Infante et al. 2003; Hinrichs et al. 2002).

    Von Health Canada zitierte Quellen (2)
    • Hinrichs R, Hunzelmann N, Ritzkowsky A, Zollner TM, Krieg T, Scharffetter-Kochanek K. Caffeine hypersensitivity. Allergy 2002;57(9):859-860. PubMed Fallbericht
    • Infante S, Baeza ML, Calvo M, De Barrio M, Rubio M, Herrero T. Anaphylaxis due to caffeine. Allergy 2003;58(7):681-682. PubMed Fallbericht

    Gilt für Produkte: providing 200 mg or more caffeine, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms such as chest pain and irregular heartbeat occur (Higgins and Babu 2013).

    Von Health Canada zitierte Quellen (1)
    • Higgins JP, Babu KM, Caffeine reduces myocardial blood flow during exercise. The American Journal of Medicine 2013;126(8):730-e 1-8.

    Gilt für Produkte: providing more than 400 mg caffeine, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if nervousness, anxiety, insomnia, tremor and/or headache occur (IOM 2001, Zhang 2001, Sawynok 1995).

    Von Health Canada zitierte Quellen (3)
    • IOM 2001: Institute of Medicine. Committee on Military Nutrition Research, Food and Nutrition Board, Institute of Medicine. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington (DC): National Academy Press; 2001 [Accessed 2023 Aug 28]. Available from: http://books.nap.edu/openbook.php?isbn=0309082587.
    • Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs 1995;49(1):37-50. PubMed Übersichtsartikel
    • Zhang WY. A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Safety 2001;24(15):1127-1142. PubMed Übersichtsartikel

    Anwendungsbedingung: All products except those making a diuretic claim1.

    When using this product diuretic effect may occur.

    1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

    Monografie von Health Canada vom 19. Dezember 2025

Sie betreffen die Zutat, nicht dieses Produkt oder seine Dosis. Sie ersetzen keinen ärztlichen Rat.

Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).

Verpackung fotografieren

Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.

Liste aus dem Jahr 2018. Fotografieren Sie die Verpackung, um Änderungen zu prüfen.

Eingabetaste zum Analysieren, Umschalt+Eingabetaste für eine neue Zeile